Game players have to 'catch' falling symbols marked with a '+' or the Credelio Plus ingredients, milbemycin oxime and lotilaner to win points, and avoid ones with fleas, ticks and worms, which lose points.
In addition to the £50 vouchers, there are goody packs for four runners up each month.
William Hawker, Parasiticides Marketing Manager at Elanco Animal Health said: "We are excited to showcase our novel new game at BVA Live with this exciting drop and offer all attendees the first chance to play Plus Plummet and win some great prizes by topping the leaderboard every month."
To play the game, visit: https://www.myelanco.co.uk/brand/plus-plummet
Incidentally, if you're at BVA Live, you're invited to join Elanco at the Exhibitor Showcase Theatre tomorrow from 09:00-09:50 for ‘Parasitology: Testing Times? Navigating the current challenges in practice’.
Cat Henstridge (BVSc MRCVS, small animal vet) will be interviewing Ian Wright (head of ESCCAP) and answering questions on everything from when to test, when to treat and how to communicate with pet owners about choice and the parasiticide treatment options available.
Photo: Elanco launches Plus Plummet at BVA Live
The service uses an Xstrahl 100 superficial radiotherapy system, a £150,000 piece of equipment installed by Paragon after it was used successfully in the USA by the hospital's medical and radiation oncology specialist, Dr Rodney Ayl.
Rodney (pictured right) says the new equipment will transform the way Paragon can treat skin cancers, dermatological disorders and some other common superficial conditions.
He said: “This is a very exciting development for us and our clients because Xstrahl systems have been used so successfully in human medicine for many years.
“This prompted us to explore adapting the SRT system for veterinary use in the UK and we hope to collaborate with Colorado State University, which has a similar unit, to develop protocols for pets.
“We believe this will be a significant advance in the treatment and care of animals and we’re delighted to be at the forefront of introducing this new service.
“It is the only one of its kind for pets in the UK and there are very few units like this anywhere in the veterinary industry, so it really is an important move forward.”
Xstrahl radiotherapy systems were originally designed for the treatment of skin cancer, dermatological disorders, certain types of benign disease and some palliative care in humans.
Rodney says that having adapted the SRT system for animals will transform their treatment and the logistics and cost of getting radiation therapy for superficial skin conditions.
He added: “Superficial radiotherapy is particularly useful for treating some types of skin cancer where it may be preferable to surgery as it can deliver excellent non-invasive outcomes with curative or palliative intent.
“The treatment is less stressful from the outset and, thanks to its mechanism of action, it is also pain-free.
“Its use of different size cones, directly over the lesion, minimises effects on healthy skin and the fast treatment means a large reduction in time and impact on the patient’s day-to-day life, while providing a highly-effective treatment.
“The machine’s flexibility also makes it particularly suited for treating multiple lesions that are difficult to access, such as the head and neck, without changing patient positioning.
“The Xstrahl 100 system will help us to respond to the growing demand for radiation treatment and we can treat these patients on an outpatient basis, helping us to reduce surgical and hospitalisation costs.
“The technology is a real winner. It is easy to use and helps us to deliver safe and effective radiotherapy to our animal patients.
“It provides a quicker, easier, cheaper and non-invasive alternative for superficial tumours, especially in geriatric patients where surgery is not always an option. We’re looking forward to seeing the positive results here at Paragon.”
For more information, visit www.paragonreferrals.co.uk.
Dr Radev faced three charges concerning his treatment of an American Bulldog in 2021.
The first charge, which contained a number of sub-charges, was that he failed to provide appropriate and adequate care to the animal.
The second was that he failed to keep adequate records.
The final charge was that his failure to keep records was misleading and dishonest.
At the outset of the hearing Dr Radev admitted that, having recognised free fluid in the dog’s abdomen, he failed to take adequate and appropriate action and failed to aspirate the dog’s abdomen with regards to the possibility of it having septic peritonitis.
He also admitted writing the clinical notes approximately two months after the event.
After considering and rejecting an application by the RCVS to amend and withdraw elements of the first charge, the Committee then considered each of the remaining sub-charges in turn.
Sub-charge 1(a) was that Dr Radev repeatedly administered meloxicam to the dog when it had recently undergone intestinal surgery and had a recent history of vomiting.
The Committee found that this was not proven.
Dr Radev said it had been administered just once and the Committee was not satisfied so as to be sure that it was repeatedly administered.
Sub-charge 1(b) (i) was that Dr Radev failed to recognise free fluid in the dog’s abdomen as shown on an ultrasound scan.
The Committee found this not proven.
Sub-charge 1(c) (i) was that Dr Radev failed to recognise the possibility of septic peritonitis in the dog.
Sub-charge 1(e) was that Dr Radev failed to provide a full medical history when referring the dog to a different practice.
The Committee found the charge not proven.
Regarding charge 2 (ii), that Dr Radev had failed to include in clinical records a reference to the colonotomy surgery, the Committee found this charge not proven as it had been provided with clinical records disproving this charge.
Finally, regarding both aspects of charge 3, namely that Dr Radev had acted misleadingly and dishonesty, the Committee found this not proven.
The Committee then considered whether the charges that Dr Radev had admitted amounted to gross misconduct in a professional respect.
In all cases it found that, while Dr Radev’s conduct had fallen below what was expected of veterinary professionals, it did not fall so far below as to constitute serious professional misconduct.
www.rcvs.org.uk/disciplinary
Abbott Animal Health is launching GLUture Topical Tissue Adhesive this month.
Abbott says GLUture is an Octyl/Butyl cyanoacrylate blend that creates a strong and flexible bond that contours to the wound site. GLUture applies purple for visibility and dries clear for a neat cosmetic appearance. Offered in an economical multi-use package with 10 applicators, GLUture's viscosity and applicator design enable flow-controlled application. GLUture topical tissue adhesive offers a flexible seal, quick application and a strong bond.
For more information, ring Abbott on 01628 644354, or visit: www.abbottanimalhealth.com
Kruuse has launched two products for the treatment of digital dermatitis in cattle: the Bovivet hoof bandage and Kruuse Hoof Gel.
According to the company, an estimated that 70% of dairy herds suffer with digital dermatitis (DD), and it is a growing problem. If not treated, it can persist for months, causing pain and lameness to infected cows. As well as worrying animal welfare concerns, numerous studies have shown that the disease can have a direct impact on milk production and reproduction with financial implications for the dairy farmer.
Traditionally, treatment has involved thoroughly washing the infected hoof, applying an antibiotic/drying agent such as salicylic acid powder and then applying a dressing that must typically remain in place for three days. This method comes with its own problems, including the difficulty dosing salicyclic acid powder correctly, the risk to the user's health when mixing, and the difficulty ensuring that the dressing is correctly applied at the right pressure and that it stays in place.
To help overcome these problems, Kruuse has introduced two products. The first is the ready-to-apply Bovivet complete Hoof Bandage. It is made from a water-repelling material that keeps out unwanted liquids. Its shape and elasticity are designed to keep the bandage in place. Inside the bandage is a treatment pad that makes for easy dosing. The outer stocking design allows for checking on the progress of treatment and for re-application if necessary. The bandage is available in two sizes, large which fits most cattle breeds, and small for calves and small breeds.
The second product, to be used in conjunction with the Bovivet Hoof Bandage, is Kruuse Hoof Gel 38%, containing 38% salicyclic acid. Kruuse says that dosing with this gel product is easier and more accurate than with the powder, making it more economical per treatment. It also reduces potential health risks to the user from inhalation of the powder when mixing.
Kruuse has produced the following instructional video to demonstrate the new products' ease of use and versatility:
Virbac has announced that Ovarid is back in stock following the resolution of a manufacturing problem.
The megestrol acetate tablets are indicated for the postponement or prevention of oestrus and the treatment of hypersexuality in male dogs. In cats they are recommended for the prevention or postponement of oestrus and the treatment of miliary dermatitis and eosinophilic granulomata.
Virbac says that because the product is relied on by the owners of many cats suffering from miliary eczema, it has worked to ensure that their welfare is not compromised by recalling unused Ovarid stock from practices to ensure that it could still be provided to those contacting them with emergency cases since the outage began in February.
Senior Product Manager Chris Geddes MRCVS said: "I'd like to express my thanks to practices for bearing with us and particularly to those which returned unused product. This meant that we were able to supply emergency supplies for the treatment of miliary eczema to every practice that asked for it. We also managed to help out some zoos which needed supplies for frisky sea lions and lions."
Ovarid is available in 20mg and 5mg tablets.
The initiative was the idea of one of the practice's client care co-ordinators, who suggested it whilst she was acting as the managing director for the day, as part of White Cross Vets' 80 year anniversary celebrations.
Managing director Tim Harrison said: "We believe we are the first veterinary practice in the UK to offer two full days paid peternity leave. Our ethos is all about caring for pets, and the first few days at home with a new addition are so special. It’s therefore essential that quality time can be dedicated to a new pet, in order to make sure they feel comfortable and safe in their new environment.
"As all of our team are all pet owners already, this time off will give them the chance to introduce and socialise any new family members with existing pets, which must be done carefully and under supervision.
"Bringing a new pet into the family takes a lot of patience and perseverance, and certain breeds or older pets can be harder to train or take longer to bond. Also there is a lot of preparation work that needs to be done in the home and garden when a young pet dog, cat or rabbit arrives, so this time off will hopefully make it easier for our team to give their new pets a safe and welcoming start in their new homes."
Other perks that White Cross Vets offers include five fully paid donation days a year to volunteer with chosen charities, a health care scheme, days off and cakes for birthdays, as well as subsidised Fitbits and gym memberships.
The study was based on VetCompass anonymised clinical records from more than two million dogs under first opinion veterinary care in the UK in 2019.
The study applied causal inference methods to the analysis of random samples of 815 dogs with CCL rupture aged between 1.5- and 12-years-old to replicate a randomised clinical trial and explore the impact of the different treatment methods.
Balancing the arms of the study for variables including age, breed and bodyweight, the researchers compared the outcomes for the dogs who received surgical management for CCL ruptures to those that were managed non-surgically.
The results showed that dogs managed surgically were 25.7% less likely to show short-term lameness at 3 months post-diagnosis and 31.7% less likely to show long-term lameness at 12 months post-diagnosis than dogs managed non-surgically.
Surgically managed dogs were 38.9% less likely to have a pain relief prescription at 3 months post-diagnosis, 34.1% less likely at 6 months and 32.7% less likely at 12 months than dogs managed non-surgically.
The RVC says these findings also similarly demonstrate lower longer term pain in surgically managed dogs.
Camilla Pegram, VetCompass PhD student at the RVC and lead author of the paper, said: “This study used an exciting new approach that allowed us to determine ‘cause’ rather than being limited to ‘association’.
"Surgical management for CCL rupture is often considered as providing better outcomes than non-surgical management, but this study now provides an evidence base to support this.
"Whilst surgical management might not always be feasible for some dogs, the findings allow vets to quantify the benefit in their discussions with owners.”
https://doi.org/10.1016/j.prevetmed.2024.106165
Reference
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
The College was ranked seventh in the medium-sized company or organisation category (50 to 449 employees) of the Best Workplaces for Women initiative.
This year is the first that the Great Place to Work Institute has run this initiative and, in making its rankings, it looked at a number of factors including the number and proportion of women in leadership positions, pay parity between men and women, workplace policies and how they support female employees, as well as training and development and mentoring.
Amanda Boag, RCVS President, said: "I am delighted that the RCVS has been recognised for being an excellent and supportive place for women to work and pleased that the hard work of the team at Belgravia House in this area has been publicly rewarded in this way.
"One of the key themes of my Presidential year is diversity and I think it is very important that, as a regulator, we reflect the veterinary profession (which is currently 63% female for veterinary surgeons and 98% female for veterinary nurses) as far as possible. With two-thirds of the staff at the RCVS being women it demonstrates that the College is largely reflective of the profession it serves.
"However, it’s not just about the numbers and with 60% of the Senior Team at the RCVS being women, including the CEO and Registrar, it demonstrates that the College has developed a culture in which women can shatter the glass ceiling and pursue leadership roles.
"Also, with policies such as flexible working hours, encouragement of home working, shared parental leave and enhanced maternity and paternity pay, the College goes the extra mile to support working parents."
Bonqat 50 mg/ml oral solution for cats contains pregabalin, an analgesic, anti-epileptic which has now been licensed for the alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.
Tessie 0.3 mg/ml oral solution for dogs contains tasipimidine and is licensed for the short-term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.
Dômes Pharma points to research which shows that in the UK 1.4 million1 dogs show signs of distress when left alone, and 4.4 million dogs1 show fear of loud noises.
In addition, over 4 million cats2 are not having routine vet checkups each year, with 26%2 of these owners reporting that it is too stressful for their cat or themselves.
Jonathan Hill, UK country manager at Dômes Pharma sid: "Dômes Pharma is excited to be launching two new innovative products to help vets manage cases in this complex area.
"These products expand our portfolio and provide essential options for owners and their pets struggling with these situational related problems."
https://www.tvm-uk.com/the-behavioural-range
The guide has been written by Simon Tappin, European and RCVS Recognised Specialist in Veterinary Internal Medicine at Dick White Referrals, and is designed to offer practical advice on the appropriate use of antibiotics in general practice. It covers a range of topics including how to create an antibiotic practice policy, ways to optimise therapy and how to limit the development of antimicrobial resistance.
Simon said: "Making rational and informed antimicrobial choices is vitally important in veterinary medicine, both for the welfare of our patients and in reducing the risk of developing antimicrobial resistance.
"Highlighting this issue to vets, providing education and supporting them in making these decisions is crucial to ensure a responsible approach to antimicrobial prescribing."
Recent surveys have highlighted the need for education on this topic, with 63 per cent of vets1 stating that they would like to improve their knowledge on antimicrobials, and 90 per cent of vets2 admitting that they are concerned about antimicrobial resistance.
In addition, there's a quiz where you can test and your knowledge on antimicrobials, and enter a competition to win an iPad Pro. The quiz can be accessed at https://veraflox.typeform.com/to/KY8lxX.
The guide is available from the Bayer Vet Centre, www.vetcentre.bayer.co.uk. Alternatively, you can download it here www.bit.ly/Veraflox2016 or contact your local Bayer Territory Manager.
References
According to data from Propellernet, there was an even bigger rise in searches for the term 'Adopt a puppy'.
Whether people are getting a dog for companionship or because they’re around more to train them, the charity says it is concerned there may be a spike in people giving up their dog when normality resumes and reality sinks in.
In order to try and prevent that, the charity has created an online quiz for potential new dog owners to test themselves on whether they are really ready to:
Owen Sharp, Dogs Trust’s Chief Executive said: "We’re encouraging potential dog owners to carry out our new test to see if you’re Dog Ready. Are you ready to be chief pooper scooper? Are you ready to forego a lie in ever again? As well as more serious questions around vet treatment and preparing for emergencies.”
Graham Norton, owner of Labradoodle Bailey, TV presenter and Dogs Trust supporter is supporting the campaign. He said: "As a dog owner myself, I know how much joy four-legged friends bring to our lives. I’ve certainly found that my gorgeous dog, Bailey, has taken the boredom out of lockdown for me, and I’ve really enjoyed spending even more time with him than usual.
"However, whilst the thought of introducing a cute, fluffy pooch to your family right now might be appealing, I fully support Dogs Trust’s important message that ‘A Dog Is For Life, Not Just For Lockdown’. Don’t forget that you still have to walk a dog on a rainy evening, and pick up their poo in the dark!"
For more information, visit dogstrust.org.uk/dogready.
Dr Corsi consulted with Kika's owners about the management of her pregnancy at the end of November 2017, finding at least 4 puppies on an x-ray taken at the time.
The first of five charges against Dr Corsi was that on the 14th December, after being advised by Kika's owners that the dog had produced two live puppies and one dead puppy the previous night, she failed to advise them that Kika needed an immediate veterinary examination.
The second charge was that, having been telephoned for a second time by the owner, she still failed to advise the owners that Kika required an immediate veterinary examination.
The third charge was that, following an examination of Kika that afternoon, and having ascertained that Kika required a caesarean section to remove one undelivered puppy, Dr Corsi failed to perform the caesarean section that day and advised the owner that Kika could undergo the caesarean section (at the practice, performed by her) the next day (or words to the effect).
The charge also stated that she failed to advise the owner that Kika’s health and welfare required the caesarean section to be performed that day; and that she failed to advise them that, if she or another veterinary surgeon at the practice could not perform the surgery that day, Kika needed to be referred to the out-of-hours clinic so that the caesarean section could take place on the 14th December.
The fourth charge was that Dr Corsi failed to recognise that Kika’s health and welfare required a caesarean section to be performed on 14th December.
The fifth charge was that, on 16th December 2017, having been telephoned by the owner at about 5pm and having been informed that Kika was weak and had not been eating post-operatively, Dr Corsi failed to advise the owner that Kika should be presented urgently for a veterinary examination.
The Disciplinary Committee considered the facts of the case and heard evidence from a number of witnesses including the owners of Kika and Dr Corsi, and from Mr Maltman MRCVS who was called as an expert witness on behalf of the College and Mr Chitty, who was called as an expert witness on behalf of Dr Corsi.
Having considered all of the evidence, the Committee found all aspects of the first and second charges proven in their entirety.
The Committee found the majority of the third charge not proved, with the exception of the fact that it found that Dr Corsi did advise the owner that she could undertake the Caesarean section on 15 December 2017.
In light of the Committee’s findings in respect of the aspects of charge three that were not proved, charge four was also found not proved.
Finally, the Committee considered that charge five was found not proved.
The Committee then went on to consider whether the charges that were found proven amounted to serious professional misconduct either individually and/or cumulatively.
Committee Chair Cerys Jones said: "In light of the evidence of both parties’ experts, the Committee was of the view that there was a risk of harm or injury resulting from Dr Corsi’s failure - the Committee decided that this was an aggravating factor.
"However, the Committee took into account that, at the time of both calls, Dr Corsi had a rationale for her decision, that she asked appropriate questions and received answers which led her to make what she considered to be a reasoned assessment.
"She had also made arrangements in both calls to be kept updated either at a pre-arranged time or sooner if Kika’s condition changed. On this basis, the Committee was satisfied that, while this was an error of judgement, it did not fall so far short of what was expected as to amount to disgraceful conduct."
Therefore, the Committee decided that while Dr Corsi’s conduct in Charges 1 and 2 demonstrated a departure from professional standards, the falling short was not so grave as to amount to disgraceful conduct in a professional respect.
The full decision can be read here: https://www.rcvs.org.uk/concerns/disciplinary-hearings/
The RCVS is looking to recruit two veterinary surgeons as part-time Postgraduate Deans, to help oversee new veterinary graduates during their Professional Development Phase (PDP).
Freda Andrews, RCVS Head of Education said: "The PDP is an online recording system to guide new graduates as they work towards achieving the "year one competences" - the competences expected of a new graduate who's had about a year's experience in practice. Postgraduate Deans monitor PDP participants' progress and respond to their queries, and ultimately sign-off the graduates once their PDP is complete."
The roles have become available as two of the current post-holders, Stephen Ware and Professor David Noakes, wish to hand over to new colleagues. Both Stephen and David have served as Postgraduate Deans since 2007, when the PDP first became a requirement for all new veterinary graduates.
Stephen said: "Being a Postgraduate Dean gives you the opportunity to assist new graduates in the early stages of their career. It is also a way to encourage employers to take a responsible attitude towards new vets, particularly during their first job or two."
Postgraduate Deans are expected to spend up to 20 days a year working mainly online from home, and attend occasional meetings at the RCVS in London. They need experience of general practice, and to be used to dealing with and advising students, or employing and supporting new graduates. A sympathetic understanding of the challenges faced by newly qualified veterinary graduates is also required.
Further information about the role can be found at www.rcvs.org.uk/jobs, and information about the PDP, including a preview, at www.rcvs.org.uk/pdp.
Applicants should send a brief CV, and a covering letter setting out their relevant experience, to education@rcvs.org.uk by 7 March 2011.
The company says the reason for the change is so that it can dedicate additional resources to the business.
Samantha Williamson, UK Country Manager at Animalcare, said: "Through our identichip microchips and our identibase pet database, we provide one of the UK’s longest-established pet microchipping services and are helping to reunite owners with their lost pets every single day.
"The pet reunification sector is evolving rapidly thanks to technological advances. We believe that the creation of identicare will facilitate the concentration of resources and expert knowledge needed to fuel the growth in our identichip business and continued enhancements to the identibase pet database. identicare will share the same passion and values as Animalcare and there will be no outward change for our customers.
“We look forward to continuing to deliver our ambition of delivering the highest quality pet reunification service under the identicare banner.”
The new company is part of the Animalcare Group.
Matthew’s award is in recognition of his paper Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom, co-authored with Laurent Garosi, which was selected by the BSAVA Committee as being the most valuable to veterinary practice.
James’ study explored data collected as part of the Small Animal Veterinary Surveillance Network (SAVSNET) at the University of Liverpool.
In total, clinical records concerning 3,150,713 consultations (917,373 dogs) were collected and analysed from 224 UK veterinary practices.
This included the management of canine generalised epileptic seizures in 517 dogs up to 6 years of age.
The study concluded that 98% of dogs presenting for a single epileptic seizure were not started on long-term therapy, in accordance with the approach recommended by the International Veterinary Epilepsy Task Force (IVETF).
Other findings from the study included:
The paper also reported on factors potentially associated with prescription of ASDs.
It stated that dogs who presented for cluster seizures (more than one epileptic seizure in a 24-hour period) were more likely to be prescribed ASDs, or to be referred to a specialist, than dogs without cluster seizures.
Dogs that were neutered or microchipped were more likely to be started on ASDs following the initial presentation, perhaps suggesting that owners who take part in regular preventative healthcare prior to the onset of their dog’s seizures could be more willing to start therapy in the earlier stages of the disease.
In addition, more than half of dogs with cluster seizures were not prescribed any ASDs.
Given that the presence of cluster seizures is typically considered an indication to start long-term therapy by the IVETF, Matthew says this may be one aspect of seizure management that could be improved in primary care practice.
Regarding the choice of anti-seizure drugs (ASDs), imepitoin was more frequently prescribed than phenobarbital in response to cluster seizures.
But unlike phenobarbital, the paper highlighted that the market authorisation for imepitoin does not include the treatment of cluster seizures.
Therefore vets should be aware that the use of imepitoin for cluster seizures should be considered as “off-licence” - and has additional implications for obtaining informed consent.
Matthew said: “We believe this research contributes to an improved understanding of the current management strategies for canine epilepsy in general practice and how this compares to the current guidelines advised by the IVETF.
"Given the prevalence of epileptic seizures within the UK canine population, as well as the large proportion of dogs that will be managed entirely within general practice without referral to a neurologist, it is vital to ensure that the level of care being provided is optimal.
"We therefore hope that this research ultimately supports and guides general practitioners in their approach to canine epilepsy, thereby improving the quality of life of affected dogs and their owners.”
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13543
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
The company says the acquisition is a natural fit for its behavioural range and will bolster its Adaptil portfolio with a wider variety of anxiety solutions for dogs.
Abbie King, senior behaviour product manager at Ceva Animal Health, said: “We have always been fans of the ThunderShirt range and we are therefore delighted with the acquisition, which will further strengthen our extensive portfolio of behavioural products that work in synergy with one another to provide pet owners with comprehensive anxiety solutions.”
For more information, visit: www.thundershirt.com
Centaur has launched a new service on the MyCentaur website which allows for 24-hour ordering from any broadband enabled computer.
A secure practice shopping list with controlled staff access to ordering and management information enables practices to safely control any buying.
According to the company, a key feature of the website is that any orders placed on line by 9pm will be delivered the following day, which gives practices even greater flexibility on ordering times over any existing vet wholesaling ordering service. As well as greater convenience, a financial benefit in using this method of ordering is that all on-line orders attract an additional two per cent discount.
The RCVS announced in a tweet yesterday afternoon that it will be retaining postnominals on the Register.
#RCVScouncil agrees to retain postnominals on Register. Proposals to improve clarity to come back to future meeting. — RCVS (@RCVS_UK) June 5, 2014
#RCVScouncil agrees to retain postnominals on Register. Proposals to improve clarity to come back to future meeting.
VetSurgeon understands that the proposals to improve clarity may yet involve some rationalisation of the postnominals that will be displayed, but that RCVS Certs and Diplomas will remain.
The decision represents something of a victory for Victoria Lilley’s campaign and yet another indication that under the stewardship of Nick Stace, the RCVS really is evolving to become a more open, responsive organisation.
California-based Signostics, Inc. has launched SpeqViewTM, billed as the world's smallest and most cost-effective veterinary ultrasound device.
Using MotionScape and SectorView technology, and offering multiple transducer frequencies, the SpeqView delivers high-resolution images for key veterinary applications including: cystocentesis; bladder volume; foreign object localization; abdominal imaging; and musculo-skeletal diagnosis.
Jeff Green, Signostics Vice-President of Sales and Marketing said: "The SpeqView provides a break-through for veterinary practices. For the first time there is an ultrasound device that is highly portable, simple to use and individually affordable. The SpeqView improves veterinary practice efficiency and income by allowing immediate diagnosis in the consulting room, or in the field and by providing better animal care.
He added: "Weighing a little over half a pound, the SpeqView features extended battery life and amazing portability, and is worn around your neck like a stethoscope or placed in your pocket until the next use."
The SpeqView is configured to use 3.5MHz and 7.5MHz transducers and comes with a comprehensive warranty, which covers the system and transducers and eliminates the need for annual service contracts. Signostics also offers extensive training and education programs delivered on site, online and in collaboration with leading veterinary institutions and educators. No interest, twelve-month financing is available.
For more information visit www.SpeqView.com or contact Signostics on 001 877 5744667.
A campaign to reform English libel law to allow for robust criticism of scientific and medical claims without fear of legal action has been launched by journalist and author Simon Singh. It's a campaign which anyone working in the caring professions might wish to support.
The campaign comes as a consequence of legal action taken against Mr Singh by The British Chiropractic Association, which took exception (perhaps unsurprisingly) to an article he'd written in The Guardian. In the article, Mr Singh denounced claims on the BCA website that its members could use spinal manipulation to treat children with colic, ear infections, asthma, sleeping and feeding conditions, and prolongued crying as 'bogus', and criticised the BCA for 'happily promoting' these claims.
Out of curiosity, VetSurgeon rang the BCA press office this morning, and asked to be given the references for studies which it feels would support the original claims made on its site. Non have been forthcoming so far, which is a surprise. Under the circumstances, we'd have expected the BCA would have a raft of supporting evidence readily available.
But this isn't really about whether or not chiropractic works or not. The case seems to hinge upon whether Mr Singh's article implied that the BCA was being deliberately dishonest, or just delusional. He say's the latter. Unfortunately for him, Mr Justice Eady recently ruled the former, leaving Mr Singh with a bill for £100,000 worth of legal fees.
Mr Singh is to appeal. At stake is the freedom to be able to challenge scientific claims without fear of being sued. If you'd like to support this campaign, visit senseaboutscience.com and add your name to the 7000 others (including some pretty illustrious names) who have already done so.